secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0000886163-24-000051
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Partner Verona Pharma gets FDA approval for Ohtuvayre (COPD); Ligand earns $5.8M milestone, $13.8M at launch
--------------------------------------------------------------------------------

- FDA approved Ohtuvayre (ensifentrine) for maintenance treatment of COPD in adults; first novel inhaled mechanism in over 20 years.
- Ligand earned a $5.8 million milestone payment; additional $13.8 million due upon commercial launch expected in Q3 2024.
- Ligand is entitled to a low single-digit royalty on potential worldwide net sales of Ohtuvayre; COPD market is multi-billion dollar.
- Verona Pharma is responsible for commercialization; Ligand relies on Verona for successful launch and sales.
- Approval triggers immediate milestone and sets stage for further payments and ongoing royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000051/0000886163-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000051/lgnd-20240627.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer